TxCell Lands $16M to Advance Immunotherapy for Crohn's
By Cormac Sheridan
Tuesday, November 27, 2012
Continuing Europe's recent push in cell therapy development, TxCell SA raised €12.4 million (US$16.1 million) in a Series C round to fund a Phase IIb study of its OvaSave autologous cell therapy in patients with refractory Crohn's disease.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.